AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03889288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device - electronic-pain killer
Description: Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
Study NCT00021242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Continuous IV infusion
Study NCT00742937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A
Description: second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
Study NCT00742937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: second capsule with vitamin E, eight days after delivery.
Study NCT04194112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: immediate urine cytology
Description: Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
Study NCT01707524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomized left versus right radial artery approach
Description: Randomized left versus right radial artery approach
Study NCT01805999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7 g Ispaghula
Study NCT01805999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 7 g placebo
Study NCT01805999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3.5g Ispaghula + 3.5 g placebo
Study NCT04210518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist
Study NCT04210518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroboscopic glasses
Description: Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
Study NCT00540917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling spray during laser treatment
Description: skin temperature measurement
Study NCT03534674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
Study NCT01687660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: apply acupuncture to prevent the migraine attack
Study NCT01687660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: apply acupuncture to prevent the migraine attack
Study NCT03530696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
Study NCT03530696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
Study NCT00484510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C)
Description: Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
Study NCT00484510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
Study NCT03915743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: complex and multi-faceted individualized palliative care
Study NCT03199690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiviral (integrase inhibitor)
Study NCT03199690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Antibiotic
Study NCT04524156 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiology
Description: Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method).
Study NCT04524156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiology
Description: Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method).
Study NCT00658853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 times 4 minutes high aerobic intensity one leg cycling
Description: 3 times per week for 10 weeks
Study NCT00966433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Description: The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
Study NCT00966433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure support Ventilation
Description: The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
Study NCT00966433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation
Description: The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
Study NCT02305979 — intervention group
Intervention type: DRUG
Intervention: Loratadine
Study NCT02204189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TongFuSan
Description: TongFuSan 1g
Study NCT04817878 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Developmental assessment
Description: Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
Study NCT00300729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Study NCT00300729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Study NCT04228939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record aftercare
Description: Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16.
Study NCT04228939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
Study NCT02490579 — intervention group
Intervention type: BEHAVIORAL
Intervention: Responses to Brief Video Messages (Facebook)
Description: Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
Study NCT02490579 — intervention group
Intervention type: BEHAVIORAL
Intervention: Response to Brief Video Messages (Clinic)
Description: Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
Study NCT02490579 — intervention group
Intervention type: BEHAVIORAL
Intervention: Response to Brief Video Messages (Social Network)
Description: Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
Study NCT00522665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 125 mg/m2 IV days 1 and 8
Study NCT00522665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 250mg/m2 IV days 1, 8 and 15
Study NCT00522665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Patients on Arm A will crossover and receive RAD001 at disease progression
Study NCT00701363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Description: 120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
Study NCT04312334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
Study NCT04312334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
Study NCT00166712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
Study NCT00166712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
Study NCT00166712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
Study NCT00166712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
Study NCT01803412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
Study NCT01803412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
Study NCT01094210 — intervention group
Intervention type: DRUG
Intervention: Fluorides, Topical
Description: 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
Study NCT02173847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Description: Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
Study NCT02173847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to cut a particular shaped graft
Study NCT02173847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Low power, near infrared diode laser for welding the surgical wound
Study NCT03082404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
Study NCT02516332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Study NCT02516332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02516332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Aerobic Exercise
Study NCT02482168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody
Study NCT02743455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA-720
Description: The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
Study NCT02743455 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA Smallpox Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
Study NCT02743455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN Yellow Fever Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
Study NCT03029221 — intervention group
Intervention type: OTHER
Intervention: PREP 8.0 curriculum developed by PREP
Description: healthy marriage and relationship education
Study NCT03029221 — intervention group
Intervention type: OTHER
Intervention: Within My Reach curriculum developed by PREP
Description: healthy marriage and relationship education
Study NCT03029221 — intervention group
Intervention type: OTHER
Intervention: Within Our Reach 8 Hours curriculum
Description: healthy marriage and relationship education
Study NCT00693667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
Study NCT00693667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
Study NCT02851888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
Study NCT02851888 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Sham Injection
Description: Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
Study NCT02851888 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General Anesthesia
Description: Patients were induced and maintained in a fashion consistent with standard practices.
Study NCT02851888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: Patients were induced and maintained in a fashion consistent with standard practices.
Study NCT02743455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
Study NCT02743455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
Study NCT02743455 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: YF Vax 17D Strain
Description: Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
Study NCT02635607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin Beta
Description: Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
Study NCT02635607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
Study NCT02635607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels>600 pg/ml; and (iii) serum LH levels>10 IU/l.
Study NCT02635607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rhCG
Description: An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
Study NCT02635607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: triptorelin
Description: 0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
Study NCT02763644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316 active drug
Description: LFG316
Study NCT02763644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: SoC (site specific)